Lentiviral Vector Promoter Selection Plate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches using lentiviral vectors face challenges in efficiently selecting promoter sequences that ensure effective gene expression and silencing, as promoter activity can vary widely across cell lines and types, leading to inefficient delivery and silencing efficiency.
Innovation Solution
The development of a plate and method for selecting promoter sequences, featuring lentiviral vectors with various promoter options such as hCMV, mCMV, hEF1α, mEF1α, CAG, hPGK, and UBC, along with reporter and miRNA scaffolding sequences, allowing for assessment of promoter activity before experiments, enabling cost-effective selection of optimal promoters for gene silencing or expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If lentiviral vectors with internal promoter regions are used, then the vectors can provide control points for transcription, but promoter activity varies widely across cell lines and cell types resulting in poor expression
Solution Approach 1:
The patent segments the promoter selection process into a systematic screening approach using multiple lentiviral vectors with different promoter regions (CMV, EF1α, CAG, PGK, UBC) tested across multiple cell lines. This segmentation allows identification of cell-type-specific optimal promoters rather than relying on a single universal promoter, thereby improving both adaptability and expression consistency.
Solution Approach 2:
The patent changes the parameter of promoter sequence selection based on cell line characteristics. By testing and comparing different promoter regions (CMV, EF1α, CAG, PGK, UBC) across various cell lines, the method optimizes the promoter parameter for each specific cell type, transforming the approach from fixed promoter usage to dynamic promoter selection based on cellular context.
2Productivity
If promoter activity is not assessed prior to experiments, then research can proceed without preliminary screening, but poor promoter selection leads to misinterpretation of delivery failure or integration failure
Solution Approach 1:
The patent implements preliminary action by requiring promoter activity assessment before conducting gene silencing or expression experiments. The method establishes a screening protocol where lentiviral vectors with different promoters are tested in advance to identify active promoters for each cell line, preventing subsequent misinterpretation of experimental failures and ensuring only validated promoters are used in downstream applications.
3Reliability
If multiple promoter sequences are tested across multiple cell lines, then optimal promoter selection is improved, but the complexity and cost of experimentation increases
Solution Approach 1:
The patent segments the complex task of promoter selection into a structured plate format with multiple loci, where each locus contains a specific promoter region (CMV, EF1α, CAG, PGK, UBC). This segmentation organizes the complexity into a systematic array that can be screened efficiently across multiple cell lines, improving selection accuracy while managing experimental complexity through standardized formatting.
Solution Approach 2:
The patent creates a universal plate design that serves multiple functions: it simultaneously tests multiple promoter regions, accommodates multiple cell lines, and provides a standardized screening platform. This multi-functional approach improves promoter selection accuracy across diverse applications while reducing overall experimental complexity by consolidating multiple tests into a single universal platform.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the efficiency of promoter selection, transduction, and gene silencing, providing a cost-effective means to design customized vectors with a higher likelihood of success, particularly in in vivo experiments using expensive animal models or primary cells.
Implementation Method 1
After entry into a cell, the viral genome, which is in the form of single-stranded RNA, is reverse transcribed to generate a double-stranded DNA
Implementation Method 2
promoter sequences that are effective in the cell type or organism of interest... providing control points for transcription
Implementation Method 3
RNAi, which involves the phenomenon of gene silencing following the introduction of double-stranded RNA (dsRNA) into cells
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Lentiviral vectors, plates, kits and methods are provided that permit improved efficiency for selection of a promoter sequence for use in a lentiviral application. Through various embodiments of the present invention, a researcher may first evaluate and then choose in a modular fashion, a vector comprising a promoter that is effective for expression in a particular cell line or type.